MedTrace Logo

VLT-015 in Patients With Schizophrenia

NCT05516121 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-08-21

No results posted yet for this study

Summary

15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.

Conditions

Interventions

DRUG

VLT-015

100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days

Sponsors & Collaborators

  • CF Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Max E Zapolski · Valentech LLC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-09-30
Completion
2022-10-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516121 on ClinicalTrials.gov